Injectable Targeted Therapy Market Report 2025

The injectable targeted therapy market size has grown rapidly in recent years. It will grow from $57.97 billion in 2024 to $64.22 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth during the historic period was driven by the increasing number of clinical trials for injectable targeted therapies, rising focus on precision oncology and immunotherapy, expanding supportive reimbursement policies for biologic therapies, growing patient preference for minimally invasive treatment options, and increasing regulatory approvals for new injectable targeted therapies.

The injectable targeted therapy market size is expected to see rapid growth in the next few years. It will grow to $95.46 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth during the forecast period is fueled by rising prevalence of chronic and rare diseases, growing demand for personalized medicine, wider adoption of biologics over conventional therapies, increasing awareness of targeted therapies among healthcare professionals, and higher investments in biotechnology and pharmaceutical research and development. The primary trends in the forecast period include technology driven innovations in monoclonal antibodies, integration of digital health platforms for patient monitoring, developments in antibody-drug conjugates, advancements in bispecific antibodies for cancer treatment, and progress in personalized medicine approaches.

The growing demand for personalized medicine is expected to drive the expansion of the injectable targeted therapy market. Personalized medicine is an approach that tailors prevention, diagnosis, and treatment based on an individual’s genetic, environmental, and lifestyle factors. This shift toward personalized medicine is largely fueled by advances in genomics, which allow for a deeper understanding of genetic variations and enable more precise treatments that enhance patient outcomes while reducing the trial-and-error approach in therapies. Injectable targeted therapy supports personalized medicine by delivering treatments that specifically target a patient’s unique molecular or genetic disease profile, improving efficacy and minimizing side effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. These new approvals included seven cancer drugs and three for other diseases. As a result, the increasing demand for personalized treatments is driving growth in the injectable targeted therapy market.

Leading companies in the injectable targeted therapy market are focusing on creating innovative solutions such as subcutaneous injections to improve drug delivery, enhance patient compliance, and target specific disease pathways more effectively. Subcutaneous injections involve delivering medication just beneath the skin into the fatty tissue, where it is gradually absorbed into the bloodstream. For instance, in August 2025, Eisai Co., Ltd., a Japan-based pharmaceutical company, partnered with Biogen Inc., a US-based biotechnology company, and received FDA approval for LEQEMBI IQLIK, a treatment for early Alzheimer's disease. This once-weekly subcutaneous injection is designed for maintenance treatment after an initial intravenous therapy, allowing patients to self-administer at home. The treatment works by targeting and clearing amyloid beta plaques and protofibrils, which contribute to Alzheimer's progression. By reducing treatment time and systemic side effects compared to intravenous infusions, the formulation offers patients greater independence and reduces the need for frequent visits to infusion centers.

In September 2025, Novartis AG, a pharmaceutical company based in Switzerland, acquired Tourmaline Bio Inc. for an undisclosed amount. This acquisition allows Novartis to enhance and diversify its cardiovascular portfolio with pacibekitug, a novel anti-inflammatory therapy that targets IL-6 to address residual inflammatory risk in atherosclerotic cardiovascular disease. With this addition, Novartis positions itself at the forefront of inflammation-driven cardiovascular treatments and aims to capture significant growth opportunities in this market. Tourmaline Bio Inc., a US-based biotechnology company, specializes in injectable targeted therapies.

Major players in the injectable targeted therapy market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Eisai Co. Ltd., Genentech Inc., Beigene Ltd., Agenus Inc., and Xilio Therapeutics Inc.

North America was the largest region in the injectable targeted therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in injectable targeted therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the injectable targeted therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Injectable targeted therapy involves medications administered through injection that precisely target specific proteins or cells responsible for a disease. This approach aims to treat conditions such as cancer more effectively while minimizing damage to healthy tissues compared to conventional treatments.

The primary types of injectable targeted therapy are monoclonal antibodies, small molecules, immunotoxins, and others. Monoclonal antibodies are laboratory-engineered antibodies designed to bind specifically to target proteins on diseased cells. The primary mechanisms of action include targeted inhibition of signal transduction pathways, targeted delivery of cytotoxic agents, and immunomodulation. These therapies are commonly administered via intravenous, subcutaneous, or intramuscular routes. They are applied across diverse fields such as oncology, cardiometabolism, immunology, infectious diseases, neuroscience, ophthalmology, and others, serving end users including hospitals, specialty clinics, and research laboratories.

The injectable targeted therapy market research report is one of a series of new reports that provides injectable targeted therapy market statistics, including injectable targeted therapy industry global market size, regional shares, competitors with an injectable targeted therapy market share, detailed injectable targeted therapy market segments, market trends and opportunities, and any further data you may need to thrive in the injectable targeted therapy industry. This injectable targeted therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The injectable targeted therapy market consists of sales of bispecific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.